F-Prime is a global venture firm investing across healthcare and technology, with a strategy centered on backing technically differentiated companies attacking large, complex markets. The firm is willing to take meaningful early risk, but only when strong domain expertise, credible validation, and a clear commercialization path support the opportunity.
F‑Prime’s investment decisions are anchored in an evidence‑driven framework that heavily weights the founding team’s domain expertise and execution track record. A compelling, quantifiable market need and early validation—whether through pilot customers in tech or pre‑clinical data in life sciences—are required before they commit capital. Traction is measured by concrete outcomes: product usage by large enterprises, clinical milestones, or clear ROI for services. Deal‑breakers include technologies with no clear go‑to‑market path, hype‑driven sectors lacking commercial proof (e.g., autonomous vehicles without revenue), and scientific programs that do not promise a step‑change in outcomes. The firm balances technical risk with commercial risk, favoring “vertical” solutions that can demonstrate early revenue or clinical impact while remaining open to backing exceptional teams at any stage.
See the rest of how F-Prime decides.
Evaluation framework, investment themes, pitch guidance and the partner map. One email, no password — we send a link and you land right back here.